ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "gout and outcomes"

  • Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting

    Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study

    Brian W Coburn1,2, Kaleb Michaud3, Debra A Bergman2 and Ted R Mikuls4,5, 1Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study  Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
  • Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting

    Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)

    JoAnne Foody1, Robin Turpin2, Beni Tidwell3 and Kathy Schulman4, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, 3ORS, Shrewsbury, MA, 4Outcomes Research Solutions, Inc., Waltham, MA

    Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
  • Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting

    Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease

    Ghaith Mitri1, Eric Wittbrodt1, Robin Turpin1, Beni Tidwell2 and Kathy Schulman2, 1Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, 2Outcomes Research Solutions, Inc., Waltham, MA

    Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences